Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177423 | 0.82 | GFER (0.72) | KDM4ERAB9ALMNASMN1; SMN2GFER | |
| SCHEMBL15762204 | 0.82 | ALDH1A1 (0.54) | KDM4ERAB9ALMNASMN1; SMN2GFER | |
| SCHEMBL2226112 | 0.82 | LMNA (0.67) | KDM4ELMNASMN1; SMN2GFERGAA | |
| SCHEMBL19031390 | 0.82 | GFER (0.72) | KDM4ERAB9ALMNASMN1; SMN2HDAC1 | |
| SCHEMBL104951 | 0.81 | KDM4E (0.58) | KDM4ERAB9ALMNASMN1; SMN2NPC1 | |
| SCHEMBL15349110 | 0.81 | KDM4E (0.49) | KDM4ERAB9ALMNASMN1; SMN2GFER | |
| SCHEMBL16603166 | 0.81 | RAB9A (0.69) | KDM4ERAB9ALMNASMN1; SMN2GFER | |
| SCHEMBL19031565 | 0.81 | NOTUM (0.47) | KDM4ERAB9ALMNASMN1; SMN2HDAC1 | |
| SCHEMBL14261150 | 0.80 | SHMT1 (0.57) | KDM4ERAB9ALMNASMN1; SMN2CYP19A1 | |
| SCHEMBL9555508 | 0.80 | LMNA (0.73) | KDM4ERAB9ALMNASMN1; SMN2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2021-04-29 | — | — | US | disclosed |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2020-03-12 | — | — | US | disclosed |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2018-12-06 | — | — | US | disclosed |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-02-23 | — | — | US | disclosed |
| US-9163043-B2 | Oxazolidinone derivatives | DONG-A ST CO., LTD. (KR) | 2015-10-20 | — | — | US | disclosed |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2014-11-27 | — | — | US | disclosed |
| US-20130281492-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | TRIUS THERAPEUTICS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-8420676-B2 | Oxazolidinone derivatives | DONG-A PHARMACEUTICALS CO. LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| CN-102702184-A | Novel oxazolidinone derivatives | DONG A PHARM CO LTD | 2012-10-03 | — | — | CN | disclosed |
| EP-2305657-A2 | Oxazolidinone derivatives | Dong-A Pharmaceutical Co., Ltd. (KR) | 2011-04-06 | — | — | EP | disclosed |
| CN-101982468-A | Novel oxazolidinone derivatives and pharmaceutical compositions comprising the derivatives | DONG A PHARM CO LTD | 2011-03-02 | — | — | CN | disclosed |
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| EP-1699784-A4 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008033934-A1 | SUBSTITUTED HETEROARYL CARBOXYLIC ACID DERIVATIVES AS PTB-1B INHIBITORS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| CN-1894242-A | Novel oxazolidinone derivatives | DONG A PHARM CO LTD (KR) | 2007-01-10 | — | — | CN | disclosed |
| EP-1699784-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | Dong-A Pharmaceutical Co., Ltd. (KR) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005058886-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | KDM4E 2360/4885RAB9A 3975/4885LMNA 4296/4885 |
| US-20130281492-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | KDM4E 2360/4885RAB9A 3975/4885LMNA 4296/4885 |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | KDM4E 2360/4885RAB9A 3975/4885LMNA 4296/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | KDM4E 950/4885RAB9A 3639/4885LMNA 4695/4885 |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | KDM4E 2360/4885RAB9A 3975/4885LMNA 4296/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | KDM4E 2578/4885RAB9A 3377/4885LMNA 4662/4885 |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | KDM4E 2360/4885RAB9A 3975/4885LMNA 4296/4885 |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | KDM4E 2360/4885RAB9A 3975/4885LMNA 4296/4885 |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | KDM4E 2360/4885RAB9A 3975/4885LMNA 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.